0000899243-22-035311.txt : 20221107 0000899243-22-035311.hdr.sgml : 20221107 20221107201913 ACCESSION NUMBER: 0000899243-22-035311 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20221103 FILED AS OF DATE: 20221107 DATE AS OF CHANGE: 20221107 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Easom Eric CENTRAL INDEX KEY: 0001914503 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-41331 FILM NUMBER: 221366916 MAIL ADDRESS: STREET 1: 171 FOREST LN. CITY: MENLO PARK STATE: CA ZIP: 94025 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: AN2 Therapeutics, Inc. CENTRAL INDEX KEY: 0001880438 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 820606654 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1800 EL CAMINO REAL, SUITE D CITY: MENLO PARK STATE: CA ZIP: 94027 BUSINESS PHONE: (650) 331-9090 MAIL ADDRESS: STREET 1: 1800 EL CAMINO REAL, SUITE D CITY: MENLO PARK STATE: CA ZIP: 94027 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-11-03 0 0001880438 AN2 Therapeutics, Inc. ANTX 0001914503 Easom Eric C/O AN2 THERAPEUTICS, INC. 1800 EL CAMINO REAL, SUITE D MENLO PARK CA 94027 1 1 0 0 Chief Executive Officer Common Stock 2022-11-03 4 S 0 11082 15.6725 D 29021 D Common Stock 2022-11-03 4 S 0 3083 16.0155 D 25938 D Common Stock 2022-11-04 4 S 0 8828 15.7991 D 17110 D Common Stock 2022-11-07 4 S 0 10167 15.9049 D 6943 D Common Stock 2022-11-07 4 S 0 2036 16.7171 D 4907 D The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. /s/ Lucy Day, Attorney-in-Fact for Eric Easom 2022-11-07 EX-24 2 attachment1.htm EX-24 DOCUMENT
                               POWER OF ATTORNEY

       Know all by these presents, that the undersigned hereby constitutes and
appoints each of Josh Seidenfeld, Anitha Anne and Nicole Mondani of Cooley LLP,
and Eric Easom and Lucy Day of AN2 Therapeutics, Inc., signing individually, the
undersigned's true and lawful attorneys-in-fact and agents to:

       (1)   execute for and on behalf of the undersigned, in the undersigned's
       capacity as an officer, director or beneficial owner of more than 10% of
       a registered class of securities of AN2 THERAPEUTICS, INC. (the
       "Company"), Forms 3, 4 and 5 (including any amendments thereto) in
       accordance with Section 16(a) of the Securities Exchange Act of 1934, as
       amended (the "Exchange Act") and the rules thereunder and a Form ID,
       Uniform Application for Access Codes to File on EDGAR;

       (2)   do and perform any and all acts for and on behalf of the
       undersigned that may be necessary or desirable to execute such Forms 3, 4
       or 5 or Form ID (including any amendments thereto) and timely file such
       forms with the United States Securities and Exchange Commission and any
       stock exchange or similar authority; and

       (3)   take any other action of any nature whatsoever in connection with
       the foregoing which, in the opinion of such attorney-in-fact, may be of
       benefit, in the best interest of, or legally required by, the
       undersigned, it being understood that the documents executed by such
       attorney-in-fact on behalf of the undersigned pursuant to this Power of
       Attorney shall be in such form and shall contain such terms and
       conditions as such attorney-in-fact may approve in such attorney-in-
       fact's discretion.

       The undersigned hereby grants to each such attorney-in-fact full power
and authority to do and perform any and every act and thing whatsoever
requisite, necessary or proper to be done in the exercise of any of the rights
and powers herein granted, as fully to all intents and purposes as the
undersigned might or could do if personally present, with full power of
substitution or revocation, hereby ratifying and confirming all that such
attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall
lawfully do or cause to be done by virtue of this power of attorney and the
rights and powers herein granted. The undersigned acknowledges that the
foregoing attorneys-in-fact, in serving in such capacity at the request of the
undersigned, are not assuming, nor is the Company assuming, any of the
undersigned's responsibilities to comply with Section 16 of the Exchange Act.

       This Power of Attorney shall remain in full force and effect until the
earliest to occur of (a) the undersigned is no longer required to file Forms 3,
4 and 5 with respect to the undersigned's holdings of and transactions in
securities issued by the Company, (b) revocation by the undersigned in a signed
writing delivered to the foregoing attorneys-in-fact or (c) as to any attorney-
in-fact individually, until such attorney-in-fact is no longer employed by the
Company or Cooley LLP.

       IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to
be executed as of February 16, 2022.

                                            /s/ Eric Easom
                                            ------------------------------------
                                            Eric Easom